证券代码：301301 证券简称：川宁生物 | | 特定对象调研 分析师会议 ☐ ☐ | | --- | --- | | 投资者关系 | 媒体采访 业绩说明会 ☐ ☐ | | 活动类别 | 新闻发布会 路演活动 ☐ ☐ | | | 现场参观 ☐ 业绩交流会 | | | 其他：电话调研 ☐ | | | 国联民生、中信证券、东方证券、国盛证券、天风证券、申 | | 参与单位名称 | 万宏源、银河证券、国投证券、中信建投、山西证券、太平 | | 及人员姓名 | 洋证券、东吴证券、中金证券、西部证券、平安证券、国金 | | | 证券、兴业证券等共 70 余人 | | 时间 | 年 月 日（周二）下午 2025 8 26 16:00~17:00 | | 地点 | 董事会办公室会议室 | | 上市公司接待 | 总经理邓旭衡先生；副总经理、财务总监李懿行先生；副总 | | 人员姓名 | 经理、首席科学家赵华先生；副总经理、销售总监姜海先生； | | | 副总经理、董事会秘书顾祥先生。 | | | 1、自年初以来公司三大中间体价格的变化情况、原因 | | | 解读及下半年预期？ | | | A：从总体来看受到医药大环境的影 ...

Group 1 - The stock price of Furida is reported at 8.43 yuan as of August 8, 2025, with a decrease of 0.01 yuan, representing a decline of 0.12% from the previous trading day [1] - The company operates in the biopharmaceutical industry, with business segments including pharmaceuticals and cosmetics, and has a total market capitalization of 8.57 billion yuan and a price-to-earnings ratio of 42.25 [1] - On August 8, the company stated on an interactive platform that it has not planned to make ergotamine its main product, addressing investor concerns regarding its product line [1] Group 2 - On August 8, the net outflow of main funds was 6.56 million yuan, accounting for 0.08% of the circulating market value, with a cumulative net outflow of 37.63 million yuan over the past five trading days, representing 0.44% of the circulating market value [1]

撰文丨王聪 编辑丨王多鱼 排版丨水成文 人类肠道细菌对复杂碳水化合物和其他大分子的降解会产生代谢物，这些代谢物被邻近的微生物用于厌氧呼吸。然而，目前尚不清楚肠道内其他膳食化合物的交 叉互养 （ cross-feeding ） 是否能驱动产生能量的氧化还原反应。 2025 年 8 月 4 日，耶鲁大学的研究人员在 Cell 子刊 Cell Host & Microbe 上发表了题为： Metabolic cross-feeding of a dietary antioxidant enhances anaerobic energy metabolism by human gut bacteria 的研究论文。 该研究发现，膳食抗氧化剂 麦角硫因 的代谢互养作用可增强人体肠道细菌的厌氧能量代谢。 共生梭菌 （ Clostridium symbiosum ） 编码的 麦角硫因酶 能将蘑菇来源的抗氧化剂 麦角硫因 （ergothioneine） 转化为电子受体 硫脲酸 （thiourocanic acid，TUA） 。这种 TUA 可被 解木聚糖拟杆菌 （ Bacteroides xylanisolvens ） 还原 ...

Project Overview - The project is named "Annual Production of 855 Tons of Green Active Raw Materials" and is initiated by Shandong Yunluo Biotechnology Co., Ltd. [2] - The total estimated investment for the project is 100 million yuan, with 7.5% allocated for environmental protection, amounting to 7.5 million yuan [2]. - The construction period is planned for one year, and the project will utilize existing factory buildings while acquiring new production equipment [2]. Production Capacity - Upon reaching full production capacity, the project is expected to produce 1 ton of probiotics, 5 tons of ergothioneine, 126 tons of ectoine, 250 tons of hydroxypropyl tetrahydropyran triol (Bosein), and 473 tons of gluconic acid annually [2][3]. - The products will be sold externally and adhere to the company's quality standards [3]. Company Background - Shandong Yunluo Biotechnology Co., Ltd. is a wholly-owned subsidiary of Shanghai Yunluo Biotechnology Co., Ltd. [3]. - The company focuses on synthetic biology, specializing in enzyme gene mining, directed enzyme modification, cell factory construction, biological fermentation, and enzyme catalysis [3]. Industry Event - The Fourth Synthetic Biology and Green Bio-Manufacturing Conference (SynBioCon 2025) will be held from August 20-22 in Ningbo, Zhejiang [5]. - The conference will focus on the integration of AI and biological manufacturing, as well as the industrialization progress and opportunities in green chemistry, new materials, future food, and agriculture [5]. - Various stakeholders, including international enterprises, industry experts, and government representatives, will participate to explore trends in biological manufacturing and innovation [5].

Project Overview - The project is named "Biopharmaceutical Raw Materials and Bio-based Materials Production Line Construction Project" [2] - It is a new construction project located in the Weinan Economic and Technological Development Zone [2] - The total investment for the project is 92.871 million yuan, with an environmental investment of 6.737 million yuan, accounting for 7.25% of the total investment [2] - The project aims to establish 9 production lines with an annual output of 200 tons of biopharmaceutical raw materials and bio-based materials, along with various supporting facilities [2] Company Profile - Shaanxi Huasen Shengbang Technology Co., Ltd. is located in the Pucheng Provincial High-tech Industrial Development Zone in Shaanxi Province [4] - The company focuses on high-end biopharmaceutical technology research and development, product manufacturing, and sales [4] - It produces biopharmaceutical intermediates and raw materials, as well as health food raw materials, and collaborates with several universities and research institutes [4] - The company has established research centers in Xi'an and Pucheng, aiming to overcome technical bottlenecks in the biopharmaceutical field through innovative microbial synthesis methods [4] Product Information - The main products currently promoted by the company include ergotioneine, rhodiola rosea glycosides, resveratrol, and tetrahydropyridine [3] Industry Event - The SynBioCon 2025 conference will be held from August 20-22 in Ningbo, Zhejiang [6] - The conference focuses on five key areas: AI + biological manufacturing, green chemistry and new materials, future food, future agriculture, and beauty raw materials [7] - It aims to explore the development trends of the biomanufacturing industry and promote the scaling of products and the transfer of scientific achievements [7]

Core Viewpoint - The strategic investment by Tuoxin Pharmaceutical in Jinsan Biotechnology highlights the growing optimism in the anti-aging market, particularly in the industrialization of ergothioneine, a rare amino acid with significant health benefits [1][6][20]. Group 1: Strategic Transformation of Tuoxin Pharmaceutical - Tuoxin Pharmaceutical, established in 2001, has evolved into a benchmark enterprise in the nucleoside raw materials sector, focusing on the development of nutritional enhancers and health products [2][4]. - The company aims to deepen its core areas while expanding into the health sector, particularly in nutritional enhancers and health foods, to create new growth points [4][20]. Group 2: Jinsan Biotechnology's Technological Breakthroughs - Jinsan Biotechnology has achieved a significant milestone by producing ergothioneine with a purity of 99.99% and a monthly production capacity of 3-5 tons, drastically reducing raw material costs by 90% [6][8]. - The company has established a cGMP production standard platform, enabling it to surpass industry standards in ergothioneine purity [8][11]. Group 3: Clinical Research and Market Expansion - Jinsan Biotechnology has expanded the application of ergothioneine beyond traditional skincare to areas such as eye health, sleep health, and liver health, with several clinical studies underway [10][11]. - The company has seen a 428-fold increase in search popularity for its ergothioneine products on Xiaohongshu, indicating strong market demand [11][20]. Group 4: Industry Impact and Global Opportunities - The collaboration between Tuoxin Pharmaceutical and Jinsan Biotechnology signifies a transformative shift in China's biopharmaceutical landscape, moving from treatment-focused approaches to preventive health and wellness [17][20]. - Jinsan Biotechnology's involvement in setting industry standards and obtaining international certifications positions it as a leader in the global health market [18][20].

Group 1 - The core point of the article is that Tuoxin Pharmaceutical has invested 10 million yuan in Jiangsu Jinsan Biotechnology Co., Ltd., acquiring a 1.75% stake, which will enhance its capabilities in the health sector [1][3] - The investment agreement stipulates that the funds will be used solely for the development and operation of Jinsan Biotechnology's main business [1] - Tuoxin Pharmaceutical is actively expanding into the health sector, developing nutritional supplements, food additives, and health foods, with successful mass production of certain functional foods [1][2] Group 2 - In 2024, Tuoxin Pharmaceutical has focused on "technological innovation, dynamic product structure optimization, and deep integration of the industrial chain" to address core business fluctuations and cultivate new growth points [2] - The company has established multiple technology platforms, including chemical synthesis and synthetic biology, and has improved the conversion of R&D results [2] - Tuoxin Pharmaceutical plans to accelerate the R&D and registration of health products over the next three years, aiming to create a complete commercialization chain [2] Group 3 - Jinsan Biotechnology specializes in the research, production, and application of ergotioneine, with breakthroughs in fermentation and purification technologies [3] - The main products of Jinsan Biotechnology include skincare products, oral capsules, and eye wash solutions [3] - Tuoxin Pharmaceutical's investment in Jinsan Biotechnology is a strategic move to extend its production, sales, and R&D chain, enhancing market competitiveness and profitability [3]

Core Viewpoint - Toxin Pharmaceutical (301089.SZ) announced an investment of 10 million yuan in Jiangsu Jinsan Biotechnology Co., Ltd., acquiring a 1.75% stake, aiming to leverage its technological advantages in the field of chemical and synthetic biology [1] Group 1: Investment Details - The investment consists of 223,400 yuan added to registered capital, with the remainder allocated to capital reserves [1] - Following the investment, Toxin Pharmaceutical will hold a direct stake of 1.75% in Jinsan Biotechnology [1] Group 2: Company Overview - Jinsan Biotechnology specializes in the research, production, and sales of synthetic biological products, focusing on the development and industrial application of ergothioneine [1] - The company has achieved breakthroughs in the entire chain of technology, including strain construction, fermentation, purification, and engineering-scale production of high-purity ergothioneine [1] Group 3: Market Potential - The market for ergothioneine terminal products in China is projected to reach 1.57 billion yuan by 2024, with 60% used in skincare and nearly 30% in health food [3] - The global ergothioneine raw material market is expected to grow from 6.3 million USD in 2024 to 16.1 million USD by 2031, with a CAGR exceeding 14% [3] Group 4: Controversies - Ergothioneine has faced controversies, including claims by a prominent biologist labeling it as a "fake drug," which has been disputed by related companies citing scientific backing [4]

拓新药业：拟对仅三生物增资1000万元 仅三生物实现了高纯度麦角硫因的制备 智通财经7月16日电，拓新药业(301089.SZ)公告称，公司将以自有资金1000万元对江苏仅三生物科技有 限公司（简称"仅三生物"）进行增资。本次交易完成后，公司将直接持有仅三生物1.75%的股权。仅三 生物成功实现了高纯度麦角硫因的制备，其主要产品包括麦角硫因护肤品、口服胶囊、洗眼液等。 ...

Industry Overview - Synthetic biology has gained significant attention from both the scientific and investment communities, with increasing research and application prospects across various fields [1][2] - The global synthetic biology market was approximately $12.2 billion in 2022, showing a year-on-year growth of 28.42%, and is projected to reach $15.1 billion in 2023 and $19 billion in 2024, with a forecast of $24.3 billion by 2025 [1] - Major countries, including the US, UK, EU, and China, are intensifying their strategic investments and policy support in synthetic biology, positioning it as a strategic high ground in future global competition [1][3] Company Developments - Haizheng Pharmaceutical has established a joint venture, Lian Sheng Synthetic, with a registered capital of 350 million yuan, aiming to enter the synthetic biology sector [2] - Shenghe Biotechnology has launched China's first production line for natural product biosynthesis, which will serve various industries including cosmetics and pharmaceuticals [2] - Lian Sheng Synthetic is set to invest 170 million yuan in a flexible production line for synthetic biology, with its first product expected to be launched in August [5] Market Dynamics - The economic value of synthetic biology and bio-manufacturing is projected to reach $100 billion by 2025, with an expectation that 60% of material production will be achieved through bio-manufacturing methods [5] - The industry is characterized by a competitive landscape where companies are striving to convert midstream technologies into marketable products, emphasizing the importance of industrialization capabilities [5][9] Challenges and Opportunities - The transition from laboratory to commercial application in synthetic biology faces multiple challenges, including technical feasibility, engineering conversion, and market adaptability [7][8] - The industry is experiencing a "valley of death" in industrialization, where many promising technologies fail to scale up due to the lack of pilot testing [8] - Despite the challenges, the integration of AI and machine learning is expected to enhance research capabilities and support the development of synthetic biology [6] Strategic Insights - The current landscape indicates a need for innovation to avoid price competition and to develop high-value products that can lead the market [9] - The establishment of supportive policies at the provincial and national levels in China is anticipated to further guide and promote the healthy development of the synthetic biology industry [6]